Rima Al-awar
Overview
- Director, Medicinal Chemistry Platform, Medicinal Chemistry
Since joining OICR, Dr. Al-awar has been recruiting scientists and developing the Medicinal Chemistry Platform within OICR. The group is dedicated to the design, synthesis and evaluation of novel anti-tumour agents. The projects within the Medicinal Chemistry Portfolio focus largely on novel targets, with specific chemical probes being created to better understand cancer signaling pathways and potential points of therapeutic intervention. The major goal of the Medicinal Chemistry group is to optimize lead molecules and progress them to drug candidates that can translate into therapeutic benefits to cancer patients.
Affiliations
| 2008 - | Director and Senior Principal Investigator, Medicinal Chemistry, Ontario Institute for Cancer Research (OICR). |
Research Output
- Song S., Christova T., Perusini S., Alizadeh S., Bao R.-Y., Miller B.W., Hurren R., Jitkova Y., Gronda M., Isaac M., Joseph B., Subramaniam R., Aman A., Chau A., Hogge D.E., Weir S.J., Kasper J., Schimmer A.D., Al-awar R., Wrana J.L., Attisano L
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers- Published Online First October 18, 2011
- Mahoney D.J., Lefebvre C., Allan K., Brun J., Sanaei C.A., Baird S., Pearce N., Grönberg S., Wilson B., Prakesh M., Aman A., Isaac M.,Mamai A., Uehling D., Al-awar R., Falls T., Alain T., Stojdl D.F
Virus-tumour Interactome Screen Reveals ER Stress Response can Reprogram Resistant Cancers for Oncolytic Virus-Triggered Caspase-2 Cell Death- Cancer Cell 2011; 20:443-456

